Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. News
  7. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inventiva : to participate at the 7th Annual Truist Securities Life Sciences Summit

04/26/2021 | 04:00pm EDT


Daix
(France), April 26, 2021Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Inventiva will participate to the upcoming 7th Annual Truist Securities Life Sciences Summit, being held virtually on May 4-5, 2021. During the event, members of the Company’s leadership will engage in 1x1 investor meetings.


The event details are as follows:

  • Format: One-on-one investor meetings
  • Participants: Frédéric Cren, Chairman, CEO and cofounder of Inventiva, and David Nikodem, Vice President of US Operations of Inventiva
  • Date: Tuesday-Wednesday, May 4-5, 2021
  • Time: 8:00 am5:00 pm (ET) / 2:00 pm11:00 pm (CET)


About Inventiva 

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com


Contacts

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00
Brunswick Group
Yannick Tetzlaff /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank

Investor relations
patti.bank@westwicke.com
+1 415 513-1284



Attachment


© OMX, source GlobeNewswire - EU Press Releases

All news about INVENTIVA
06/09Inventiva announces three scientific presentations at the EASL International ..
GL
05/25INVENTIVA  : to participate at the Jefferies Virtual Healthcare Conference
GL
05/14INVENTIVA  : reports first quarter 2021 financial information and updates on the..
PU
05/13GLOBAL MARKETS LIVE : Walt Disney, Canada Goose, Tod's, Burberry, Sonos...
05/13INVENTIVA  : AbbVie to Initiate Phase 2B Study of Autoimmune Disease Drug
MT
05/12Inventiva reports first quarter 2021 financial information and updates on the..
GL
05/12INVENTIVA  : reports first quarter 2021 financial information and updates on the..
GL
04/26INVENTIVA  : to participate at the 7th Annual Truist Securities Life Sciences Su..
AQ
04/26INVENTIVA  : to participate at the 7th Annual Truist Securities Life Sciences Su..
GL
04/20INVENTIVA  : Appointment of Martine Zimmermann as Independent Director to Invent..
AQ
More news
Financials
Sales 2021 3,42 M 4,14 M 4,14 M
Net income 2021 -51,4 M -62,3 M -62,3 M
Net cash 2021 71,8 M 87,0 M 87,0 M
P/E ratio 2021 -8,58x
Yield 2021 -
Capitalization 477 M 579 M 578 M
EV / Sales 2021 119x
EV / Sales 2022 275x
Nbr of Employees 91
Free-Float 72,0%
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 25,13 €
Last Close Price 12,36 €
Spread / Highest target 345%
Spread / Average Target 103%
Spread / Lowest Target -2,91%
EPS Revisions
Managers and Directors
NameTitle
Frédéric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Chris Buyse Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVENTIVA5.46%579
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966